Bisphenol A and Its Analogues Activate Human Pregnane X Receptor by Sui, Yipeng et al.
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 3 | March 2012  399
Research
There is growing concern about the possible 
adverse health effects posed by endocrine-
disrupting chemicals (EDCs), which can 
interfere with an organism’s complex endocrine 
signaling mechanisms and have deleterious 
consequences (Diamanti-Kandarakis et al. 
2009). One EDC in particular, bisphenol A 
(BPA), has attracted considerable attention and 
controversy. BPA is among the world’s highest 
production volume chemicals, with > 8 billion 
pounds produced each year (Vandenberg et al. 
2010). BPA, a base chemical used extensively 
in poly  carbonate plastics, is present in many 
consumer products (Bondesson et al. 2009; 
vom Saal et al. 2007). More than 80 bio-
monitoring studies indicate that human 
exposure to BPA is ubiquitous globally, 
and most of the U.S. population (> 90%) is 
exposed to BPA (Vandenberg et al. 2010).
BPA has been detected in human blood, 
urine, tissues, and other fluids, and higher 
levels have been detected in infants and chil-
dren than in adults (Vandenberg et al. 2010). 
Numerous animal studies indicate that even 
low-level exposures to BPA may cause adverse 
health effects in humans (Bondesson et al. 
2009; Vandenberg et al. 2010; vom Saal et al. 
2007), and higher BPA exposure has been 
associated with diabetes and cardio  vascular 
disease in the general adult U.S. popula-
tion (Lang et al. 2008; Melzer et al. 2010). 
Despite evidence of adverse effects of BPA in 
humans, the under  lying mechanisms remain 
elusive. BPA, regarded as a xeno  estrogen, is 
a weak agonist of the estrogen receptor (ER) 
(Bondesson et al. 2009). Nevertheless, doubts 
remain whether BPA exerts adverse estrogenic 
effects in animals and humans (Sharpe 2010; 
Vandenberg et al. 2009).
Many EDCs, including organochlorine 
and organophosphate pesticides, alkyl  phenols, 
phthalates, and polychlorinated biphenyls 
(PCBs) activate another nuclear receptor, 
the pregnane X receptor (PXR; also known 
as steroid and xeno  biotic receptor, or SXR) 
(Zhou et al. 2009b). PXR is a xeno  biotic 
sensor that regulates clearance via induction 
of genes involved in drug and xeno  biotic 
metabo  lism (Zhou et al. 2009b). Recently, 
PXR has been implicated in lipid homeo  stasis, 
athero  sclerosis, and carcino  genesis (Sui et al. 
2011; Wang et al. 2011; Zhou C et al. 2009a; 
Zhou J et al. 2006).
BPA can activate human PXR (hPXR) 
and induce target gene expression in human 
cells (Tabb et al. 2004; Takeshita et al. 2001). 
However, the detailed mechanism by which 
BPA exerts these effects remains unknown. 
Numerous BPA analogues and derivatives, 
including bisphenol B (BPB), bisphenol F 
(BPF), bisphenol S (BPS), brominated deriva-
tive bisphenols [e.g., tetrabromo  bisphenol A 
(TBBPA)], and chlorinated bisphenols [e.g., 
tetra  chloro  bisphenol A (TCBPA)], are used 
in commodity products (Cobellis et al. 2009; 
Shi et al. 2009). Although BPB, TBBPA, and 
TCBPA have been detected in human serum 
and tissues (Cobellis et al. 2009; Fernandez 
et al. 2007; Shi et al. 2009), it is not known if 
these environmental chemicals activate PXR 
in a manner similar to that of BPA.
Here we report that BPA is a potent ago-
nist for hPXR but not for mouse or rat PXR 
(mPXR and rPXR, respectively). Cell-based 
reporter assays, in silico ligand–PXR docking 
studies, and site-directed mutagenesis were 
combined to study the inter  action between 
BPA and PXR. Several BPA analogues also 
functioned as hPXR agonists. Moreover, we 
observed that combinations of BPA and cer-
tain analogues work synergistically to activate 
PXR and induce PXR target gene expression 
in human LS180 cells. These studies reveal 
that hPXR is a target of BPA and suggest that 
some effects of BPA in humans may arise in 
part from PXR activation.
Materials and Methods
Reagents and plasmids. BPA, pregnenolone 
16α-carbonitrile (PCN), rifampicin (RIF), 
and 2,2-diphenyl  propane (DPP) were pur-
chased from Sigma-Aldrich (St. Louis, MO). 
BPA β-d-glucuronide was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). 
All other BPA analogues were purchased from 
TCI America (Portland, OR). All chemi-
cals were dissolved in dimethyl sulfoxide 
(DMSO). hPXR and mPXR expression vec-
tors; GAL4 DNA-binding domain (DBD)-
linked nuclear receptor ligand-binding domain 
(LBD) vectors; VP16-hPXR, GAL4-NCoR, 
GAL4-SMRT, GAL4-SRC1, GAL4-PBP, and 
CMX–β-galactosidase expression vectors; and 
hPXR reporter (CYP3A4XREM-luciferase), 
mPXR reporter [(CYP3A2)3-luciferase], and 
GAL4 reporter (MH100-luciferase) have been 
described previously (Blumberg et al. 1998; 
Tabb et al. 2004; Zhou et al. 2007).
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Ba c k g r o u n d: Bisphenol A (BPA) is a base chemical used extensively in many consumer   products. 
BPA and its analogues are present in environ  mental and human samples. Many endocrine-
  disrupting chemicals, including BPA, have been shown to activate the pregnane X receptor (PXR), 
a nuclear receptor that functions as a master regulator of xeno  biotic metabolism. However, the 
detailed mechanism by which these chemicals activate PXR remains unknown. 
oB j e c t i v e: We investigated the mechanism by which BPA interacts with and activates PXR and 
examined selected BPA analogues to determine whether they bind to and activate PXR.
Me t h o d s : Cell-based reporter assays, in silico ligand–PXR docking studies, and site-directed muta-
genesis were combined to study the interaction between BPA and PXR. We also investigated the 
influence of BPA and its analogues on the regulation of PXR target genes in human LS180 cells.
re s u l t s: We found that BPA and several of its analogues are potent agonists for human PXR 
(hPXR) but do not affect mouse PXR activity. We identified key residues within hPXR’s ligand-
binding pocket that constitute points of interaction with BPA. We also deduced the structural 
requirements of BPA analogues that activate hPXR. BPA and its analogues can also induce PXR 
target gene expression in human LS180 cells.
co n c l u s i o n s: The present study advances our understanding of the mechanism by which BPA 
interacts with and activates human PXR. Activation of PXR by BPA may explain some of the 
adverse effects of BPA in humans.
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Site-directed mutagenesis. hPXR full-
length plasmid was used as a wild-type tem-
plate to generate a series of mutant plasmids 
by using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent, Santa Clara, CA) 
according to the manufacturer-supplied pro-
tocol. The primers used for mutant generation 
are listed in Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1104426).
Cell culture and transfections. The 
human hepatic cell line HepG2 and intestine 
epithelial cell line LS180 were obtained from 
American Type Culture Collection (Manassas, 
VA). Cells were transfected using FuGENE 6 
(Roche Diagnostics, Indianapolis, IN), and 
luciferase and β-galactosidase activities were 
determined as previously described (Tabb 
et al. 2004; Zhou et al. 2007). For the mam-
malian two-hybrid assays, HepG2 cells were 
transfected with GAL4 reporter, VP16-hPXR, 
and GAL4-SRC1, GAL4-PBP, GAL4-SMRT, 
or GAL4-NCoR plasmids. The cells were 
then treated with compounds at the indi-
cated concentration. Cytotoxicity was assessed 
using the 3-(4,5-dimethy  thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay 
(Mosmann 1983).
RNA isolation and quantitative real-time 
polymerase chain reaction (QPCR) analysis. 
Total RNA was isolated from LS180 cells using 
TRIzol reagent (Life Technologies, Carlsbad, 
CA) according to the manufacturer-supplied 
protocol. QPCR was performed as described 
Figure 1. Species-specific activation of PXR by BPA. (A and B) HepG2 cells were transfected with full-length hPXR together with a hPXR reporter (CYP3A4-luc; A) 
or full-length mPXR together with an mPXR reporter [(CYP3A2)3-luc); B] and CMX–β-galactosidase control plasmid. Cells were then treated with DMSO (con-
trol), BPA, RIF (hPXR ligand), or PCN (mPXR ligand) for 24 hr. (C) HepG2 cells were co-transfected with hPXR together with CYP3A4-luc reporter and CMX–β-
galactosidase plasmid; cells were then treated with BPA or RIF at concentrations 0.1–100 μM for 24 hr. (D) HepG2 cells were co-transfected with a GAL4 reporter 
and a series of GAL4 constructs in which the GAL4 DBD is linked to the indicated nuclear receptor LBD; cells were treated with DMSO or 5 μM BPA for 24 hr. 
Abbreviations: FXR, farnesoid X receptor; LXRα, liver X receptor-α; PPARα and PPARγ, peroxisome proliferator-activated receptor-α and -γ; RARα, retinoid acid 
receptor-α; RXR, retinoid X receptor; VDR, vitamin D receptor. (E and F) HepG2 cells were transfected with a GAL4 reporter and VP16-hPXR, as well as expression 
vector for GAL4 DBD or GAL4 DBD linked to the receptor interaction domains of the indicated PXR coactivators (GAL4-SRC1 and GAL4-PBP; E) or corepressor 
(GAL4-SMRT and GAL4-NCoR; F). Cells were then treated with DMSO, BPA, RIF, or PCN for 24 hr. Error bars indicate SEM.
*p < 0.05, **p < 0.01, and #p < 0.001 compared with control (n = 3–5 per group).
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BPA  –  1  5  10  20  –  –  –  –  –  –  –
RIF  –  –  –  –  –  1  5  10  20  –  –  –
PCN  –  –  –  –  –  –  –  –  –  5  10  20
BPA  –  1  5  10  20  –  –  –  –  –  –  –
RIF  –  –  –  –  –  1  5  10  20  –  –  –
PCN  –  –  –  –  –  –  –  –  –  5  10  20
BPA  –  1  5  10  20  –  –  –  –  –  –  –
RIF  –  –  –  –  –  1  5  10  20  –  –  –
PCN  –  –  –  –  –  –  –  –  –  5  10  20
BPA  –  1  5  10  20  –  –  –  –  –  –
RIF  –  –  –  –  –  5  10  20  –  –  –
PCN  –  –  –  –  –  –  –  –  5  10  20
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previously (Sui et al. 2011). The primers are 
listed in Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1104426).
Computational docking studies. The 
structural coordinates of the tethered hPXR, 
linker, steroid receptor coactivator 1 (PXR/
SRC-1) were retrieved from the RSCB Protein 
Data Bank entry 3HVL (RSCB Protein Data 
Bank 2012; Wang et al. 2008). The larger 
PXR fragment of chain A, Gly142-Glu458, 
was extracted for molecular modeling using 
MOE 2010 software (Chemical Computing 
Group, Montreal, Quebec, Canada), and for 
ligand-receptor docking studies using GOLD 
software (version 5.0) (Payne and Glen 1993). 
Water molecules, salt ions, ligand (SR12813), 
and coreceptor fragments were deleted. After 
the addition of hydrogen atoms and assigning 
of the AMBER99 force-field charges to the 
protein, the hydrogen atomic positions were 
allowed to relax (Wang et al. 2000). The 
resulting protein structural coordinates were 
saved in Tripos mol2 format and used later for 
GOLD docking.
The ligands were docked to the 3HVL 
chain A using semi  flexible docking whereby 
the ligand has full conformational flexibility 
and the hydroxyl groups of designated protein 
side chains in the binding pocket can rotate to 
optimize hydrogen bond contacts. Each ligand 
was docked 50 independent times. The bind-
ing pocket was defined as all the atoms within 
an 8-Å radius around the bound ligand, 
SR12813. For muta  genesis study, we per-
formed local energy minimization after each 
in silico mutation and compared the back-
bone root-mean-square deviation (RMSD) of 
the wild-type and mutated folds in the region 
of the PXR binding pocket. The calculated 
RMSD was < 1.0 Å in all cases, so alteration 
in protein folds was minimal.
Statistical analysis. Statistical analysis of 
the luciferase reporter assays was performed 
using a two-sample, two-tailed Student’s 
t-test, with p < 0.05 regarded as significant. 
One-way analysis of variance was used when 
multiple comparisons were made, followed 
by Dunnett’s t-test for multiple comparisons 
with controls.
Results
Species-specific activation of PXR by BPA. 
In mammals, PXR exhibits considerable 
differences in its pharmacology, in part because 
of the remarkable divergence in its LBD across 
species (Blumberg et al. 1998; Zhou et al. 
2009b). We first tested the ability of BPA to 
activate hPXR or mPXR using transfection 
assays. The potent species-specific PXR 
ligands rifampicin (RIF) and pregnenolone 
16α-carbonitrile (PCN) were used as the 
positive control for hPXR and mPXR, 
respectively. BPA strongly induced hPXR 
reporter activities in a dose-dependent manner 
(Figure 1A) but had no effect on mPXR activity 
(Figure 1B). BPA elicited no toxicity to the 
cells at tested concentrations as revealed by the 
MTT assay [Supplemental Material, Figure 1 
(http://dx.doi.org/10.1289/ehp.1104426)]. 
Dose–response analysis indicated that the half-
maximal effective concentration (EC50) for 
BPA activation of hPXR-mediated cytochrome 
P450 3A4 (CYP3A4) promoter activity was 
about 9 μM (Figure 1C). 
To determine whether BPA acts specifically 
on hPXR, we evaluated the ability of BPA to 
activate a number of other nuclear receptors, 
including rPXR, human retinoid acid receptor 
(RAR)α, retinoid X receptor (RXR), farnesoid 
X receptor (FXR), liver X receptor (LXR)α, 
peroxisome proliferator-activated receptor 
(PPAR)α, PPARγ, vitamin D receptor 
(VDR), and ERα (Figure 1D). BPA had 
little, if any, effect on activation of these other 
nuclear receptors, with the exception of ERα 
(Figure 1D); therefore, we focused our attention 
on BPA-mediated PXR agonism. These data 
suggest that BPA is a species-selective agonist of 
hPXR, but not mPXR and rPXR, similar to the 
species selectivity of RIF for hPXR compared 
with mPXR and rPXR.
Nuclear receptor coregulators play critical 
roles in nuclear receptor activation. We used 
the mammalian two-hybrid assay to evalu-
ate whether BPA affects the inter  action of 
PXR with coactivators or corepressors. Both 
RIF and BPA strongly promoted the specific 
interaction of steroid receptor coactivator-1 
(SRC1) and peroxisome proliferator–activated 
receptor-binding protein (PBP) in a dose-
dependent manner (Figure 1E). Unliganded 
hPXR was able to interact with the corepres-
sors nuclear receptor corepressor (NCoR) and 
silencing mediator of retinoid and thyroid 
hormone (SMRT; Figure 1F). Similar to RIF, 
BPA promotes the dissociation of hPXR from 
NCoR or SMRT (Figure 1F). In contrast, 
PCN had no effect on the inter  actions of 
hPXR with the coactivators (Figure 1E) or 
corepressors (Figure 1F). Binding of BPA to 
hPXR inhibits PXR/corepressor inter  action 
and promotes PXR coactivator recruitment, 
thereby inducing hPXR transcriptional activa-
tion in a concentration-dependent manner.
Computational docking and modeling 
studies. We implemented a structure-based 
computational approach to investigate the 
potential inter  action pattern between BPA and 
PXR. BPA was docked into the X-ray crystal 
structure of hPXR–SR12813 co  complex after 
removal of the ligand (Wang et al. 2008). 
After 50 independent docking exercises, a 
single orientation was identified for BPA 
in the ligand-binding pocket of hPXR. 
BPA forms a hydrogen bond with one 
PXR side chain and additional inter  actions 
with 10 other residues (Figure 2). BPA can 
position either one of its para hydroxyl 
groups on the phenol rings and can orient 
itself to form a strong O–H–O hydrogen 
bond (calculated 2.4 Å) with the side chain of 
Ser247. This dominant inter  action appears to 
Figure 2. Computational docking of BPA to the ligand-binding pocket of the hPXR apoprotein X-ray crystal structure (3hvl.pdb). (A) The BPA–hPXR complex. The 
PXR LBD is shown in ribbon presentation (red, helix; yellow, strand); BPA (phenyl ring, green) occupies only a small portion of the large ligand-binding pocket 
of PXR. (B) BPA forms a hydrogen bond (light blue dotted line) with Ser247 and van der Waals contacts with several other hydrophobic residues, particularly 
Phe288, Trp299, and Tyr306. (C) An interaction map of BPA and hPXR, which reveals that BPA occupies only a small portion of the large, flexible PXR ligand-
binding pocket. 
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secure the ligand in a localized region of the 
ligand-binding pocket, leaving a significant 
portion of the cavity unoccupied. Nonpolar 
contacts also play a key role in stabilizing 
BPA within the ligand-binding pocket. The 
Ser247 hydrogen-bonded phenolic ring of 
BPA appears to form a 3.4-Å edge-to-face 
contact with the side chain of Tyr306 and a 
4.0-Å hydro  phobic contact with Phe288, and 
is surrounded by the hydrophobic side chains 
of Met243 and Met246. The other phenol 
ring of BPA is stabilized by π–π stacking 
interactions (3.6 Å) with the side chain of 
Trp299 and hydrophobic contacts (4.1 Å) 
with Leu324. The two methyl groups in the 
linker engage in hydrophobic interactions 
with Val211 and Trp299.
Based on visual analysis, the docked BPA 
ligand lacks direct contact with activation 
function 2 (AF-2) helix (αAF) of the PXR 
AF-2 surface. However, Ser247, which forms 
hydrogen bonds with BPA, is located in close 
proximity to the AF-2 residues Met425 and 
Phe429. These indirect inter  actions between 
BPA and the AF-2 surface may stabilize the 
active AF-2 conformation of the receptor and 
contribute to the agonistic activity of BPA on 
hPXR (Figure 2B,C).
Regarding the selectivity of BPA for hPXR 
over mPXR, sequence alignment of the LBDs 
of mPXR and hPXR revealed that the most 
divergent region of the PXR ligand-binding 
pocket for these two species is located at the 
conformationally flexible base of the cavity. 
This variable region includes two additional 
β-strands unique to PXR and a flexible loop 
(residue 308–321). Leu308 in hPXR, which 
lies in the C-terminus of the β4-strand, is 
replaced by Phe in mPXR. Given the greater 
size and rigidity of Phe compared with Leu, 
one might surmise from this substitution 
alone the absence of BPA agonistic activity 
in mPXR. In this case, Leu308 may play a 
key structural role in specific activation of 
hPXR by BPA.
Key LBD residues of PXR are required for 
BPA’s agonistic activity. Guided by the results 
from the docking analysis, we mutated the key 
amino acids predicted as responsible for BPA’s 
agonistic activity: Ser247, Phe288, Trp299, 
Tyr306, and Leu308. Thr248, a key amino acid 
known to be important for PXR/coactivator 
interaction, was mutated as the positive 
control in this study. For negative controls, 
we used residues within PXR’s ligand-binding 
pocket predicted by the docking analysis not 
to interact with BPA: Cys284, Met323, and 
Leu411. As shown in Figure 3A, Ser247Leu, 
Phe288Ala, Trp299Leu, Tyr306Phe, and 
Leu308Phe mutations completely blocked 
the agonistic activity of BPA. In addition, 
Phe288Ala, Trp299Leu, and Leu308Phe 
mutations abolished BPA’s agonistic activity 
but had little effect on the activity of RIF. 
As expected, Thr248Leu mutation abolished 
the activity of both BPA and RIF, whereas 
Cys284Ser, Met323Leu, and Leu411Phe 
had negligible effects on BPA. Interestingly, 
Ser247Leu blocked the activity of both BPA 
and RIF, although Ser247Ala partially restored 
the activity of RIF.
In the dose–response assays for several 
mutants (Figure 3B), we observed that the 
Phe288Ala, Trp299Leu, and Leu308Phe PXR 
Figure 3. Key residues of PXR LBD are required for BPA’s agonistic activity. (A) Agonistic activity of BPA 
and RIF in HepG2 cells co-transfected with a full-length hPXR wild-type (WT) plasmid or mutant hPXR 
plasmids, together with CYP3A4-luc reporter and CMX–β-galactosidase plasmid and treated with control 
medium (medium plus DMSO) or medium containing 10 μM BPA or RIF for 24 hr. (B) Dose–response assay 
showing agonistic activity of BPA in HepG2 cells transiently transfected with a full-length hPXR plasmid or 
mutant hPXR plasmids, as well as CYP3A4-luciferase reporter and CMX–β-galactosidase plasmid, followed 
by the incubation with control medium or medium containing BPA. Error bars indicate SEM.
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Ser247Ala
BPA log [concentration] (µM) BPA log [concentration] (µM)
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Ser247Leu
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Phe288Ala
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Trp299Leu
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Tyr306Phe
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
Leu308Phe
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0
10
20
30
40
50
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
Met323Leu
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
Leu411Phe
F
o
l
d
 
a
c
t
i
v
a
t
i
o
n
WT Ser247Leu Ser247AlaP he288AlaT rp299Leu Thr248Leu Cys284Ser Met323Leu Tyr306PheL eu308Phe Leu411Phe
Control
BPA 10 µM
RIF 10 µM
Control
hPXR-WT
hPXR-Ser247Ala
Control
hPXR-WT
hPXR-Phe288Ala
Control
hPXR-WT
hPXR-Tyr306Phe
Control
hPXR-WT
hPXR-Met323Leu
Control
hPXR-WT
hPXR-Ser247Leu
Control
hPXR-WT
hPXR-Trp299Leu
Control
hPXR-WT
hPXR-Leu308Phe
Control
hPXR-WT
hPXR-Leu411PheBPA and its analogues are human PXR ligands
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 3 | March 2012  403
mutants were weakly activated by BPA at high 
concentrations (e.g., 25 or 50 μM); however, 
the Ser247Ala, Ser247Leu,, and Tyr306Phe 
mutants were inactive even at these concentra-
tions. As for the negative controls, Leu411Phe 
did not affect BPA’s agonistic activity, whereas 
Met323Leu diminished activity only slightly. 
In summary, our site-directed muta  genesis 
analysis confirmed predictions from the dock-
ing study and revealed specific key residues 
within the ligand-binding pocket of PXR that 
play a significant role in the agonistic effects 
of BPA.
Identification of BPA analogues as hPXR 
agonists. In addition to BPA, many BPA 
analogues and derivatives are also present 
in the environment and found in human 
samples. Consequently, we next tested a series 
of structural analogues of BPA to determine 
whether they can also activate PXR (Figure 4A). 
We found that several of these BPA analogues, 
including BPB, 2-(4´-hydroxyphenyl)-2-
phenylpropane (HPP), and bisphenol AF 
(BPAF), could activate hPXR in a dose-
dependent manner (Figure 4B). BPB and 
HPP were more potent than BPA as hPXR 
agonists at a low concentration (5 μM), and 
had comparable agonistic effects at high 
concentrations (10 and 25 μM). BPAF was a 
relatively weak PXR agonist compared with 
BPA. Similar to BPA, none of them activated 
mPXR (Figure 4C). The other BPA analogues 
tested, including TCBPA, TBBPA, BPF, BPS, 
bisphenol AD (BPAD), and DPP, did not 
activate PXR. Interestingly, BPA-glucuronide, 
the major BPA metabolite in animals and 
humans, did not activate PXR [Supplemental 
Material, Figure 2 (http://dx.doi.org/10.1289/
ehp.1104426)]. The glucuronide moiety may 
preclude BPA from interacting with PXR.
These results provide sufficient informa-
tion for us to propose a rudimentary struc-
ture–activity relationship for PXR agonistic 
activity of BPA and its analogues. Specifically, 
the mini  mum requirement for hPXR agonis-
tic activity is the presence of at least one para 
phenolic group. This feature is exemplified by 
the agonistic activity of BPA and HPP but not 
DPP. Furthermore, the two methyl groups 
in the linker between the phenolic rings are 
critical for BPA’s activity; losing one methyl 
group (BPAD) or both methyl groups (BPF) 
or replacing the C(CH3)2 linker of BPA by 
a sulfone group SO2—as in BPS—abolished 
agonistic effect. However, the analogue in 
which each of the CH3 groups in the linker 
are replaced by CF3 (BPAF) retained partial 
agonistic activity. Interestingly, the inability of 
TCBPA and TBBPA to activate hPXR suggests 
that the presence of the bromine or chlorine 
atoms proximal to the phenolic –OH weakens 
or disrupts on the O–H–O hydrogen bond 
with Ser247. This influence of the halogen 
atoms may be caused by electronic (induction, 
resonance) effects, steric effects, or both.
BPA and analogues synergistically acti-
vate hPXR. Because of the large and flexible 
LBD of PXR, combinations of BPA and other 
EDCs may activate hPXR in an additive or 
synergistic manner. To explore this possibil-
ity, we examined mixtures of BPA with each 
of the analogues under study at various con-
centrations. These experiments revealed that 
BPA and HPP can activate PXR synergisti-
cally (Figure 5A). A mixture of 2 μM BPA 
Figure 4. BPA analogues activate hPXR. (A) Chemical structure of BPA analogues. (B and C) HepG2 cells were transfected with (B) full-length hPXR together with 
CYP3A4-luc reporter or (C) full-length mPXR together with (CYP3A2)3-luc reporter and CMX–β-galactosidase control plasmid. Cells were treated with DMSO (  control) 
or BPA analogues for 24 hr. RIF (B) and PCN (C) were used as positive controls. Error bars indicate SEM.
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and 2 μM HPP activated PXR and induced 
PXR-mediated reporter activity > 30-fold, 
whereas BPA or HPP alone at 4 μM induced 
reporter activity only 4- and 13-fold, respec-
tively. Mixtures of BPB and HPP synergis-
tically activated PXR in a similar manner 
(Figure 5A). These results show that combina-
tions of BPA-like agonists can work synergis-
tically to activate hPXR. In contrast, DPP, 
which lacks PXR agonistic activity, failed 
to affect the agonistic activity of BPA, BPB, 
or HPP [Supplemental Material, Figure 3 
(http://dx.doi.org/10.1289/ehp.1104426)].
In view of HPP’s agonistic activity, we com-
putationally docked HPP in the PXR binding 
pocket [see Supplemental Material, Figure 4 
(http://dx.doi.org/10.1289/ehp.1104426)]. 
HPP binding was similar to that of BPA, 
although with a more optimal inter  action with 
Trp299. Regarding the observed synergistic 
agonist activity of combinations of BPA and 
HPP, computational alignment of their sepa-
rate binding poses supported the possibility that 
both BPA and HPP may bind to hPXR simul-
taneously and still maintain hydrogen bonding 
inter  actions with Ser247 (Figure 5B).
BPA and analogues induce PXR target 
gene expression in human cells. Because BPA 
and certain structural analogues are selective 
agonists for hPXR over mPXR, we used the 
human intestinal cell line LS180 to test the 
effect of BPA and analogues on PXR target 
genes. LS180 cells were treated with the sol-
vent control, positive control (RIF), BPA, or 
an analogue of BPA (BPB or HPP) at various 
concentrations. Total RNA was isolated, and 
quantitative PCR (QPCR) was performed to 
detect the expression levels of PXR target genes 
involved in phase 1 [CYP3A4 (cytochrome 
P450, family 3, subfamily A, polypeptide 4], 
phase 2 [UGT1A1 (UDP glucuronosyl-
transferase 1 family, poly  peptide A1)], and 
phase 3 [MDR1 (multi  drug resistance pro-
tein 1 or ATP-binding cassette, sub-family B 
(MDR/TAP), member 1)] metabolism. As 
shown in Figure 6, BPA significantly induced 
the expression of mRNA encoding the PXR 
target genes CYP3A4, UGT1A1, and MDR1 
in a dose-dependent manner compared with 
solvent controls. Consistent with the reporter 
assays, BPB and HPP also acted as PXR ago-
nists and induced PXR target gene expression 
in LS180 cells.
Discussion
Despite increasing evidence that exposure to 
BPA causes adverse health effects in humans, 
controversy remains about the specificity and 
mechanism of those effects (Vandenberg et al. 
2009). Although BPA is a xeno  estrogen, its 
endocrine-disrupting effects cannot be entirely 
attributed to its estrogenic activity. More 
mecha  nistic studies are urgently needed to 
explore BPA’s effects on other signaling path-
ways. Masuyama et al. (2000) reported that 
BPA has no effect on mPXR-mediated tran-
scription. Later studies found that BPA can 
activate hPXR and induce PXR target genes 
in human primary cells (Tabb et al. 2004; 
Figure 5. BPA and analogues BPB and HPP synergistically activate PXR. (A) Activation of PXR in HepG2 cells transfected with full-length hPXR together with 
CYP3A4-luc reporter and CMX–β-galactosidase plasmid, and then treated with BPA, BPB, HPP, or mixtures. Error bars indicate SEM. (B) Docking poses of BPA 
(yellow) and HPP (green) in the binding pocket of hPXR. BPA and HPP may maintain hydrogen bond with Ser247; however, the orientation of the benzene ring of 
HPP is better than that of BPA for π-stacking interaction toward Trp299 (red).
*p < 0.05, **p < 0.01, and #p < 0.001 compared with the untreated group or groups treated with a single compound (n = 3). 
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Figure 6. BPA and analogues regulate hPXR target gene expression. Human LS180 intestinal epithelial cells were treated with control medium (medium plus 
DMSO) or medium containing BPA, BPB, HPP, or RIF. Total RNA was isolated and gene expression levels were analyzed by QPCR with primers for human 
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Takeshita et al. 2001). In the present study, we 
sought to determine and explore the mecha-
nism by which BPA interacts with and activates 
PXR. We found that BPA is a potent agonist 
for hPXR but not for mPXR and rPXR. We 
further identified the key residues within PXR’s 
ligand-binding pocket inter  acting with BPA by 
combining analyses of computational docking 
and site-directed mutagenesis. Several struc-
tural analogues of BPA, including BPB, HPP, 
and BPAF, were identified as hPXR agonists. 
Our findings suggest that hPXR is a target of 
BPA and certain analogues and that activa-
tion of PXR by BPA may contribute to BPA’s 
adverse effects in humans.
A fundamental question about all EDCs 
is whether low-dose exposure to EDCs can 
influence human endocrine functions. Here 
we present experimental results that show, for 
the first time, that BPA and specific analogues 
can synergistically activate hPXR. Although 
BPA activates hPXR at relatively high con-
centrations in vitro (~ 2 μM), combinations 
of BPA and numerous other EDCs may addi-
tively or synergistically activate hPXR in vivo. 
Additional in vivo studies are required to estab-
lish the influence of such synergistic or additive 
effects in risk assessment, because exposure to 
mixtures of chemicals is much more represen-
tative of real-world scenarios. If additive or 
synergistic effects are confirmed under in vivo 
conditions, then PXR-mediated effects of BPA, 
even at low doses, must be assessed within the 
context of the influence of coexisting EDCs.
The computational modeling studies, in 
concert with site-directed mutagenesis analysis, 
demonstrated their utility to predict, visualize, 
and quantify the binding of novel ligands of 
nuclear receptors at the molecular level. Among 
the series of structural analogues of BPA tested, 
several, including BPB and HPP, exhibited 
activity as hPXR agonists. The variability in 
PXR activity among these close structural 
analogues of BPA illustrates that even slight 
alteration of the BPA structure can translate 
to dramatic effects on the compound’s ability 
to activate PXR. Based on the docking studies 
and reporter assays, we deduce that an essential 
hydrogen bonding interaction with Ser247 and 
extensive hydrophobic contacts with receptor 
residues are structural requirements of BPA 
analogues that activate hPXR. The critical 
hydrogen bond with Ser247 localizes BPA 
into a hydrophobic region of the PXR ligand-
binding pocket lined by Phe288, Trp299, 
and Tyr306. These three residues are highly 
conserved across species and interact with 
structurally diverse PXR agonists, as evidenced 
by multiple PXR crystal structures. Numerous 
hydrophobic contacts between BPA and PXR 
further stabilize ligand binding and indirectly 
promote contact with the AF-2 region, thus 
facilitating proper orientation of αAF to 
interact with coactivators.
Activation of hPXR by BPA may con-
tribute to adverse effects and should be con-
sidered in future risk assessment studies of 
BPA in humans. For example, human BPA 
exposure has been positively associated with 
cardio  vascular disease in epidemiological stud-
ies (Lang et al. 2008; Melzer et al. 2010). 
However, mechanisms that may be respon-
sible for these associations remain largely 
unknown. To our knowledge, BPA has not 
been shown to have athero  genic effects in ani-
mal models. Recently, we have demonstrated 
PXR’s atherogenic effects in animal models 
(Sui et al. 2011; Zhou et al. 2009a). In addi-
tion, chronic activation of mPXR by PCN was 
reported to increase athero  sclerosis in apolipo-
protein E–deficient mice (Zhou et al. 2009a). 
Because BPA is an agonist for hPXR, chronic 
activation of hPXR by exposure to BPA may 
lead to increased atherosclerosis development 
and cardio  vascular disease risk in humans.
Conclusion
We have shown that BPA and several analogues 
are potent agonists for hPXR but not mPXR. 
Computational docking studies and site-directed 
muta  genesis analysis identified key residues 
within PXR’s ligand-binding pocket that inter-
act with BPA. The BPA analogues BPB, HPP, 
and BPAF were also identified as hPXR ago-
nists. Interestingly, combinations of BPA with 
certain agonistic analogues acted synergistically 
in activating PXR. The present study highlights 
the importance of the choice of animal model in 
the human risk assessment of BPA. 
We hope that findings from this study 
will stimulate further investigations of BPA 
and its analogues, in particular the mecha-
nism by which BPA activates hPXR, the spe-
cies specificity of BPA activation of PXR, and 
the prospect of additive or synergistic effects 
of BPA and BPA-like agonists on hPXR in 
combination with each other or with other 
EDCS. Activation of PXR by BPA, alone or 
in combination with analogues or a wider 
array of EDCs, may explain at least some of 
the adverse health effects in humans.
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